“Wow! The American people are so excited to know now that!” US Sen. Bernie Sanders sarcastically said of Trump’s false prescription drugs claim.

Sen. Bernie Sanders (I-VT) speaks at a Senate confirmation hearing for Dr. Heidi Overton on September 24, 2026 at the US Capitol in Washington, DC.
(Photo by Tasos Katopodis/Getty Images)
Brad Reed
Sep 24, 2026
CO,MMON DREAMS
Sen. Bernie Sanders on Thursday grilled President Donald Trump’s nominee to lead the US Food and Drug Administration about the president’s false claims about the price of prescription drugs in the US.
During a Senate confirmation hearing, Sanders (I-Vt.) asked Dr. Heidi Overton about Trump’s boast at this year’s State of the Union address about giving Americans the cheapest medications of any country in the world.
“President Trump has claimed... that he took prescription drugs from the highest price in the entire world to the lowest,” Sanders said in an incredulous tone.
“Wow!” he continued sarcastically. “The American people are so excited to know now that we pay the lowest prices in the world for prescription drugs.”
“What do you think?” Sanders asked Overton. “Are we paying the lowest prices in the world for prescription drugs?”
“Senator... there has been immense progress, especially on individual products,” Overton replied. “Right now, 89% of branded drugs have signed agreements to lower their prices and make that available...”
Sanders at this point interjected.
“Do we pay the lowest prices?” he asked. “The president said it. He’s your boss... He just said we pay the lowest prices in the world for prescription drugs. It’s true or it’s not true. Is it true?”
“Senator, we have seen...” Overton began.
“Is it true that we pay the lowest prices in the world for prescription drugs, as President Trump has said?” Sanders persisted.
“So, senator, the results that we have seen for the American people... have dropped prices,” she replied. “And right now [the Consumer Price Index] says that, for the first time in 60 years, prescription drug prices have gone down by 3%.”
“Which may have something to do with the legislation that we passed several years ago,” said Sanders, in reference to provisions in the 2022 Inflation Reduction Act that granted Medicare the power to negotiate lower prices for certain prescription drugs.
Even if Trump’s policies were solely responsible for a 3% drop in drug prices, that would not make them the lowest in the world by any stretch of the imagination.
A 2024 study from the RAND Corporation found that Americans pay nearly three times as much for prescription drugs compared to the rest of the world.
Sanders’ office last year released a report showing that, during the first year of Trump’s second term, drug companies raised prices on 688 medications, with a median increase of 5.5%.
Trump has a long history of making false claims about reducing prescription drug costs, and has even said that he has slashed them by as much as 600%, which would mean that pharmaceutical companies are paying consumers to take their medications.
“The Trump team appears to be doing more to protect pharma profits than patients’ pocketbooks,” said Public Citizen.

AstraZeneca CEO Pascal Soriot (left) shakes hands with U.S. President Donald Trump in the Oval Office of the White House as Health and Human Services Secretary Robert F. Kennedy Jr. stands by on October 10, 2025 in Washington, DC.
(Photo by Andrew Harnik/Getty Images)
Brett Wilkins
Sep 20, 2026
COMMON DREAMS
The Trump administration’s secretive deals with Big Pharma to lower prescription drug prices included benefits for the companies that were not publicly disclosed, according to documents obtained by the consumer advocacy group Public Citizen via a Freedom of Information Act request and published Saturday.
Public Citizen said the deals allow drugmakers to raise prices overseas and limit the scope of promised savings for American patients.
“Trump’s drug pricing deals are a mirage, designed to convince Americans that he’s taken significant action on drug pricing while creating minimal, if any, downside for Big Pharma,” Peter Maybarduk, director of Public Citizen’s Access to Medicines program, said Saturday.
“The texts show Trump handing out favors to Big Pharma, undercutting his own models to lower prices, and throwing the support of the US government behind corporate decisions to deny medicines entirely to other countries,” he added.
The disclosures come as President Donald Trump continues to tout his “most-favored nation” (MFN) drug-pricing initiative. On Friday, the administration announced that all 50 states, Washington, DC, and Puerto Rico had applied to participate in a Medicaid program built around MFN pricing, under which participating drugmakers are supposed to offer certain medicines at prices comparable to those charged in other wealthy nations.
However, Public Citizen said the newly disclosed contracts raise questions about how much patients will actually save. The deal with Eli Lilly excludes the company’s blockbuster GLP-1 drugs Mounjaro and Zepbound from the definition of products subject to certain MFN discounts. Public Citizen said a similar carveout for Novo Nordisk could reduce potential Medicaid savings by $1.7 billion.
Eli Lilly’s agreement also permits the company to stop supplying a medicine to another country under certain circumstances, removing that nation’s price from the calculation used to determine the US MFN price.
“That practice threatens patients’ health,” Public Citizen said, adding that such provisions could effectively encourage pharmaceutical companies to make medicines unavailable abroad rather than reduce US prices.
“By agreeing to terms that endorse and facilitate pharma companies discontinuing supplying drugs in other countries, so they can continue to charge US customers more, the Trump team appears to be doing more to protect pharma profits than patients’ pocketbooks,” it said.
Public Citizen also said that the documents do not publicly reveal the full scope of tariff exemptions and other incentives provided to drugmakers, including reported benefits involving expedited US Food and Drug Administration reviews. The Pfizer agreement indicates that the company may share additional revenue generated by higher prices abroad with the US government. But crucial portions are redacted, leaving the public unable to determine how much money is involved, who receives it, or how it would be spent.
“The Trump administration continues to favor secrecy in these limited disclosures under FOIA today,” Maybarduk said, noting that the government has blacked out “the prices, product lists, and information needed to assess whether Trump accomplished anything of substance.”
Public Citizen’s disclosures follow months of criticism over Trump’s claims that his administration has dramatically reduced drug prices. In August, Sen. Elizabeth Warren (D-Mass.) accused the administration of failing to make the agreements public despite Health and Human Services Secretary Robert F. Kennedy Jr.'s previous commitment to provide them, saying, “still crickets.”





